NASDAQ:ECOR

electroCore Competitors

$1.96
-0.10 (-4.85 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.96
Now: $1.96
$2.06
50-Day Range
$1.96
MA: $2.20
$2.81
52-Week Range
$0.74
Now: $1.96
$3.63
Volume892,696 shs
Average Volume4.05 million shs
Market Capitalization$95.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Competitors

electroCore (NASDAQ:ECOR) Vs. EDAP, EYES, BSGM, FONR, IRIX, and NDRA

Should you be buying ECOR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to electroCore, including Edap Tms (EDAP), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), FONAR (FONR), IRIDEX (IRIX), and ENDRA Life Sciences (NDRA).

Edap Tms (NASDAQ:EDAP) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Edap Tms and electroCore's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$50.23 million5.30$1.69 million$0.06152.33
electroCore$2.39 million39.76$-45,150,000.00($1.54)-1.27

Edap Tms has higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

5.5% of electroCore shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Edap Tms and electroCore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edap Tms-4.03%-11.54%-5.78%
electroCore-792.01%-109.15%-79.64%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Edap Tms and electroCore, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edap Tms00303.00
electroCore00503.00

Edap Tms presently has a consensus target price of $12.50, indicating a potential upside of 36.76%. electroCore has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Edap Tms.

Risk and Volatility

Edap Tms has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Summary

Edap Tms beats electroCore on 7 of the 13 factors compared between the two stocks.

Second Sight Medical Products (NASDAQ:EYES) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Second Sight Medical Products and electroCore's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Second Sight Medical Products$3.38 million60.95$-33,590,000.00($1.91)-4.64
electroCore$2.39 million39.76$-45,150,000.00($1.54)-1.27

Second Sight Medical Products has higher revenue and earnings than electroCore. Second Sight Medical Products is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

4.1% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 5.5% of electroCore shares are held by institutional investors. 67.5% of Second Sight Medical Products shares are held by company insiders. Comparatively, 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Second Sight Medical Products and electroCore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Second Sight Medical ProductsN/A-977.63%-291.02%
electroCore-792.01%-109.15%-79.64%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Second Sight Medical Products and electroCore, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Second Sight Medical Products0000N/A
electroCore00503.00

electroCore has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Second Sight Medical Products.

Risk and Volatility

Second Sight Medical Products has a beta of 2.49, meaning that its share price is 149% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Summary

electroCore beats Second Sight Medical Products on 7 of the 13 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BioSig Technologies and electroCore, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
electroCore00503.00

electroCore has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than BioSig Technologies.

Earnings & Valuation

This table compares BioSig Technologies and electroCore's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
electroCore$2.39 million39.76$-45,150,000.00($1.54)-1.27

BioSig Technologies has higher earnings, but lower revenue than electroCore.

Risk and Volatility

BioSig Technologies has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 5.5% of electroCore shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by company insiders. Comparatively, 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares BioSig Technologies and electroCore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
electroCore-792.01%-109.15%-79.64%

Summary

electroCore beats BioSig Technologies on 6 of the 10 factors compared between the two stocks.

electroCore (NASDAQ:ECOR) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for electroCore and FONAR, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
electroCore00503.00
FONAR0000N/A

electroCore presently has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, equities research analysts clearly believe electroCore is more favorable than FONAR.

Valuation & Earnings

This table compares electroCore and FONAR's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
electroCore$2.39 million39.76$-45,150,000.00($1.54)-1.27
FONAR$85.69 million1.42$8.24 millionN/AN/A

FONAR has higher revenue and earnings than electroCore.

Risk and Volatility

electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of electroCore shares are held by institutional investors. Comparatively, 62.1% of FONAR shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Comparatively, 8.6% of FONAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares electroCore and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
electroCore-792.01%-109.15%-79.64%
FONAR8.28%5.57%3.99%

Summary

FONAR beats electroCore on 7 of the 12 factors compared between the two stocks.

electroCore (NASDAQ:ECOR) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for electroCore and IRIDEX, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
electroCore00503.00
IRIDEX00203.00

electroCore presently has a consensus target price of $3.70, indicating a potential upside of 88.78%. IRIDEX has a consensus target price of $6.50, indicating a potential downside of 10.96%. Given electroCore's higher possible upside, equities research analysts clearly believe electroCore is more favorable than IRIDEX.

Valuation & Earnings

This table compares electroCore and IRIDEX's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
electroCore$2.39 million39.76$-45,150,000.00($1.54)-1.27
IRIDEX$43.45 million2.61$-8,810,000.00($0.64)-11.41

IRIDEX has higher revenue and earnings than electroCore. IRIDEX is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of electroCore shares are held by institutional investors. Comparatively, 32.6% of IRIDEX shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Comparatively, 2.0% of IRIDEX shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares electroCore and IRIDEX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
electroCore-792.01%-109.15%-79.64%
IRIDEX-21.54%-38.60%-24.99%

Summary

IRIDEX beats electroCore on 7 of the 13 factors compared between the two stocks.

electroCore (NASDAQ:ECOR) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for electroCore and ENDRA Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
electroCore00503.00
ENDRA Life Sciences0000N/A

electroCore presently has a consensus target price of $3.70, indicating a potential upside of 88.78%. Given electroCore's higher possible upside, equities research analysts clearly believe electroCore is more favorable than ENDRA Life Sciences.

Valuation & Earnings

This table compares electroCore and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
electroCore$2.39 million39.76$-45,150,000.00($1.54)-1.27
ENDRA Life Sciences$10,000.0010,566.40$-13,310,000.00($2.34)-1.09

ENDRA Life Sciences has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

electroCore has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of electroCore shares are held by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are held by institutional investors. 24.9% of electroCore shares are held by company insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares electroCore and ENDRA Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
electroCore-792.01%-109.15%-79.64%
ENDRA Life SciencesN/A-492.76%-288.58%

Summary

electroCore beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.


electroCore Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$9.14-1.5%$266.36 million$50.23 million-152.33
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.86-5.4%$206.00 million$3.38 million-4.64Unusual Options Activity
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.57-2.0%$145.28 millionN/A0.00Gap Up
FONR
FONAR
1.1$18.62-1.2%$122.04 million$85.69 million17.57News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.30-1.4%$113.30 million$43.45 million-13.27
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.54-1.6%$105.66 million$10,000.00-1.38News Coverage
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.21-2.5%$96.47 millionN/A-1.59News Coverage
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.86-3.3%$41.27 million$1.50 million-1.02
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.25-5.2%$33.61 million$6.57 million-0.01Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.40-1.9%$32.60 million$5.51 million-0.11Analyst Upgrade
News Coverage
Gap Down
STRR
Star Equity
0.1$3.30-2.7%$16.24 million$114.18 million-1.05Gap Up
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.